BlossomHill Therapeutics

BLSM Director Carl Gordon Buys $10M in Open-Market Purchase

by
SEC Form 4 filing document showing an insider stock purchase disclosure for BlossomHill Therapeutics

A fresh Form 4 filing shows Carl L. Gordon, a director of BlossomHill Therapeutics, Inc. (BLSM), purchased 625,000 shares of the company on the open market on August 10, 2026. The transaction, priced at $16.00 per share, totaled $10,000,000.00 — a purchase made with the insider’s own funds rather than acquired through options or other … Read more

BLSM Insider Buy: OrbiMed Advisors Spends $10M on Shares

by
Illustration of an SEC Form 4 filing document showing an insider stock purchase by OrbiMed Advisors LLC in BlossomHill Therapeutics

A director of BlossomHill Therapeutics, Inc. (BLSM) put real money on the table this week. According to a Form 4 filing, OrbiMed Advisors LLC purchased 625,000 shares of BlossomHill on August 10, 2026, in an open-market transaction priced at $16.00 per share. The total outlay came to an even $10,000,000.00, funded directly by the insider … Read more